Compare SYRE & IMOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYRE | IMOS |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 980.5M |
| IPO Year | 2016 | N/A |
| Metric | SYRE | IMOS |
|---|---|---|
| Price | $33.59 | $28.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $55.50 | N/A |
| AVG Volume (30 Days) | ★ 745.7K | 21.4K |
| Earning Date | 11-04-2025 | 11-11-2025 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $748,307,671.00 |
| Revenue This Year | N/A | $5.78 |
| Revenue Next Year | N/A | $10.84 |
| P/E Ratio | ★ N/A | $132.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.91 | $12.78 |
| 52 Week High | $35.31 | $30.98 |
| Indicator | SYRE | IMOS |
|---|---|---|
| Relative Strength Index (RSI) | 69.14 | 58.47 |
| Support Level | $33.24 | $28.63 |
| Resistance Level | $35.31 | $30.00 |
| Average True Range (ATR) | 1.79 | 0.71 |
| MACD | 0.16 | -0.17 |
| Stochastic Oscillator | 79.12 | 69.67 |
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.